



FORM PTO-1449/A and B (modified) (10/01/07) (TO/SB/08)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/024,607	ATTY. DOCKET NO.: B0801.70231US00
FILING DATE: November 8, 2001	CONFIRMATION NO.: 6830
APPLICANT: Richard T. Lee	
GROUP ART UNIT: 1646	EXAMINER: B. D. Hissong

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials *	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials *	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials *	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/BH/		VIDAL et al., Prognostic Value of Cytokines and Neurohormones in Severe Heart Failure, Rev Esp Cardiol 2002; 55(5):481-6.	
/BH/		NOZAKI et al., Soluble Tumor Necrosis Factor Receptors are Elevated in Relation to Severity of Congestive Heart Failure, Jpn Circ J 1997; 61:657-64.	
/BH/		ORUS et al., Prognostic Value of Serum Cytokines in Patients with Congestive Heart Failure, J Heart Lung Transplant 2000; 19:419-25.	

EXAMINER:

/Bruce Hissong/

DATE CONSIDERED:

03/24/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).